Cancer Risk in JIA Is Not a Treatment Effect

“These data are reassuring, compared with the data the FDA released. The FDA looked at all children exposed to any TNF inhibitor, including etanercept, infliximab, and adalimumab. And not just JIA but other diseases associated with an increased risk of cancer, such as inflammatory bowel disease,” Dr. Southwood said.

“Any chronic, inflammatory disease is probably linked with cancer because it likely interferes with the normal pathway that detects cancer, he added.

These data are reassuring, compared with what the FDA released, showing a cancer signal in children.

Source DR. SOUTHWOOD

Lymphopro-liferative cancer remains uncommon, despite the increased relative risk in JIA.

Source DR. ASKLING